Tingting Ma

Efficacy of photodynamic therapy for cervical intraepithelial neoplasia grade 3: a retrospective study

This study aimed to evaluate the histologic response rate of high-grade squamous intraepithelial lesion (HSIL), also referred to as cervical intraepithelial neoplasia 3 (CIN 3), following treatment with 5-aminolevulinic acid photodynamic therapy (ALA-PDT). A retrospective analysis was conducted on 49 patients diagnosed with CIN 3 and treated with ALA-PDT between March 2022 and December 2024. Patients received either ALA-PDT alone or in combination with the Loop Electrosurgical Excision Procedure (LEEP) or CO Among the 44 patients with complete follow-up, the total response rate was 85.19% (23/27) for ALA-PDT alone and 88.24% (15/17) for combination therapy, yielding an overall response rate of 86.36% (38/44). The double-negative rate (negative for both HPV and histopathology) was 100%. When stratified by age group, pathology-negative outcomes-considered effective treatment responses-were observed in 100% of patients younger than 20, 80% of those aged 21-30, 93.7% in the 31-40 age group, and 100% in patients over 40. The total effective rates across different cervical transformation zones (TZ) were 75% (18/24) for TZ1, 100% (12/12) for TZ2, and 100% (8/8) for TZ3. Negative HPV conversion rates were 82.35% (28/34) in the HPV16/18-positive group, 80% (8/10) in the non-HPV16/18 group, and 73.33% (11/15) in the multiple high-risk HPV group. ALA-PDT demonstrates favorable efficacy and stability in patients with HSIL/CIN 3, offering clinicians an additional option for managing these cervical lesions.

Long-term follow-up of photodynamic therapy of cervical intraepithelial neoplasia grade 2 (CIN2)

To determine the long-term efficacy and safety of 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) for treating cervical intraepithelial neoplasia grade 2 (CIN2) as well as the suitability of ALA-PDT in treating of cervical lesions divided into cervical transformation zone type 3. We included 81 patients diagnosed with CIN2 at the Department of Gynecology of the Affiliated Hospital of Qingdao University with data collected between January 2019 and January 2021 following ALA-PDT. Furthermore, we analyzed the superiority of ALA-PDT in fertility preservation among women of childbearing age based on follow-up data from 11 patients with fertility requirements. Our findings confirmed the long-term efficacy of ALA-PDT for CIN2 treatment, with an overall efficacy of 95.83 % (23/24) at follow-up of 25-36 months. Moreover, the cervical transformation zone type 3 improvement and human papillomavirus (HPV)-negative efficacy were 69.2 % (18/26) and 82.4 % (14/17), respectively. ALA-PDT is recommended for consenting patients with cervical transformation zone type 3. Additionally, women without primary infertility could experience natural pregnancy and full-term birth of more than one baby following ALA-PDT for CIN2 treatment, with a satisfaction rate of ≈100 %. ALA-PDT is recommendable for treating high-grade squamous intraepithelial lesions, especially in patients with fertility requirements.

Application of 5-aminolevulinic acid photodynamic therapy for vaginal intraepithelial neoplasia, a report of six cases

Vaginal intraepithelial neoplasia (VAIN) has a high-risk for recurrence and may precede genital cancers, such as vaginal cancer and/or other invasive diseases. Human papillomavirus (HPV)-induced VAIN may occur after loop electrosurgical excision procedures (LEEPs) or panhysterectomy. 5-aminolevulinic acid (ALA) photodynamic therapy (ALA-PDT) has demonstrated utility in preventing the recurrence of cervical intraepithelial neoplasia (CIN); however, evaluation of its effect on VAIN has not been performed. The effectiveness of ALA-PDT was evaluated in 6 women diagnosed with HPV-induced VAIN. Lesion treatment was performed 3 h after ALA using light at a wavelength of 635 nm and light density of 80 mw/cm Six women, aged 49-54 years, who were diagnosed VAIN grade 1/2 or 2 after LEEP or panhysterectomy or no surgery underwent ALA-PDT (range, 4-8 treatments). Four of the 6 women were HPV negative on retesting 3-4 months after ALA-PDT. Most patients exhibited no signs of recurrence during the follow-up period. Direct use of ALA-PDT or after panhysterectomy did not necessarily lead to a negative result; however, ALA-PDT after LEEP or panhysterectomy combined with LEEP yielded a satisfactory curative effect on VAIN. Although recurrence rates need to be monitored in longer-term studies, the absence of post-treatment complications in this study supports the potential utility of the technique.

Clinical outcome of photodynamic therapy for the treatment of cervical intraepithelial neoplasia grade 2

Five-aminolaevulinic acid photodynamic therapy (ALA-PDT) was used to treat 79 cervical intraepithelial neoplasia 2 (CIN 2) patients who desired preservation of fertility ,between Oct 2018 and Dec 2020. Three months after treatment, among the 65 patients who returned for follow-up, full recovery and improvement rates were 43/65 and 16/65, respectively, resulting in a total response rate of 90.77%. This suggests that ALA-PDT is worthy of clinical application, even as monotherapy. The result of immune testing also indicated significant promotion of CD4+T expression during the recovery process, highlighting the importance of immune responses in different prognoses.